BRIEF-Roche CEO expects biosimilar competition from 2015

ZURICH Thu Jan 30, 2014 1:52am EST

Related Topics

ZURICH Jan 30 (Reuters) - Roche Holding AG : * CEO says expects biosimilars for rituxan in 2016 and herceptin in 2015 * CEO says net debt to assets ratio is back within target range, at 11 percent * CEO says will continue to look out for bolt on buys, would not want to give a

specific range

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.